Welcome to the home of ISoP's new Special Interest Group (SIG) on Quantitative Systems Pharmocology. This SIG will be a forum for discussion and information sharing between members of ISoP with a interest in systems pharmocology.
To advance the development and utilization of safe and efficacious medicines through the application of Quantitative Systems Pharmacology (QSP)
Consistent with this Vision, we will:
QSP SIG Leadership Team
Michael G. Zager (Chair)
Dr. Zager is an associate scientific director in the clinical pharmacology organization at Janssen Pharmaceutical Companies of Johnson & Johnson. Starting at Janssen in November 2013, Mike has primarily focused on partnering with discovery and early development project teams, assisting in preclinical PKPD plans and analyses, quantitatively assessing exposure-response relationships, and providing human efficacious exposure and dose projections. Mike’s passion is in the preclinical space and loves working with teams to hunt for drugs. Mike relies on a variety of modeling methods for drug hunting, from basic PKPD to quantitative systems pharmacology. Prior to Janssen, Mike spent 8 years at Pfizer, where he was part of a team of PKPD modelers that successfully created a paradigm where quantitative PKPD modeling and human efficacious dose projections are now standard practice for preclinical compounds nominated for NME status. Prior to Pfizer, Mike was a postdoctoral trainee at the U.S. EPA human health research center in North Carolina, and he received his Ph.D. in computational mathematics at North Carolina State University in 2003.
Valeriu Damian (Vice Chair)
Valeriu Damian is leading the Modeling and Translational Biology group in GlaxoSmithKline and is responsible for providing translational modeling support for all therapeutic areas in GSK. This includes Quantitative Systems Pharmacology/Toxicology (QSP/QST) modeling, Physiological Based Pharmacokinetics and drug delivery modeling (PBPK), as well as PK/PD, TK/TD modeling. Valeriu holds a PhD in computer science from University of Iowa and a computer engineering diploma from Politehnica University of Bucharest in Romania. His carrier with GSK started over 17 years ago as a senior scientist in the Bioinformatics department initially responsible for the mathematical analysis and modeling of gene expression and proteomics data. As a manager in the Scientific Computing and Mathematical Modeling in GSK, he focused on developing tools for Systems Biology pathway modeling. Before taking the leadership role for the Modeling and Translational Biology he spent a few years as a director in the Open Innovation team in GSK where he worked on using sensors technologies to improve variability of clinical outcomes and non-invasive imaging technologies to validate model predictions. Valeriu focus has been on integrating diverse scientific ideas from multiple disciplines – mathematics, informatics, chemistry, physics, biology and engineering – into mechanistically based models and demonstrated their capability to interpret available data, to enhance understanding, to suggest testable hypotheses, to push the scientific boundaries and ultimately to bring better, faster and more affordable medication to the patients. Some of the areas of in which Valeriu has made significant contributions include: systems biology modeling, microarray data analysis, pathway and disease modeling, quantitative systems pharmacology models (QSP), powder modeling – applied to the inhaled drugs, lung deposition modeling, modeling of medical devices and packaging, drug stability modeling, physiology based modeling (PBPK) including detailed ocular, inhaled, long acting parenterals and transdermal drug delivery.
Eric Sobie (Chair-elect)
Eric Sobie is a biomedical engineer by training and a systems pharmacologist by choice. He received his B.S. degree from Duke University, and his Ph.D. from Johns Hopkins, both in Biomedical Engineering. After postdoctoral training at the University of Maryland, he established an independent laboratory in the Department of Pharmacology at Icahn School of Medicine at Mount Sinai. At Mount Sinai, his NIH-funded laboratory aims to uncover fundamental mechanisms and improve drug development by combining physiological experiments with mathematical modeling. Specifically, his group has made important advances in understanding differences between individuals in response to pro-arrhythmic drugs, in using modeling to identify targets with improved anti-arrhythmic properties, and in developing algorithms to distinguish between dangerous and safe cardiac drugs. In addition to running a research laboratory, Eric also serves as Associate Dean for Programmatic Development in Mount Sinai’s graduate school.
Coen van Hasselt (Secretary)
Coen van Hasselt is an assistant professor of quantitative systems pharmacology at Leiden University, Netherlands, and currently also a Marie Curie research fellow at the Ravi Iyengar laboratory at the Icahn School of Medicine at Mount Sinai, New York. Coen received his MSc in Pharmaceutical Sciences from Leiden University, Netherlands and a PhD degree focusing on quantitative pharmacology in oncology from Utrecht University, Netherlands. During his PhD Coen also registered as a board-certified clinical pharmacologist. Coen then worked as postdoctoral fellow at Leiden University focusing on PBPK modeling applied to antimicrobial drugs. His current research interests are the use of omics approaches to inform PKPD and QSP based models, applied to cardiotoxicity, oncology and infectious diseases.
Saroja Ramanujan (Past-Chair)
Dr. Ramanujan is a Senior Scientist leading the Translational and Systems Pharmacology group at Genentech Inc. She received her BSE in chemical engineering from the University of Michigan and a PhD from the University of Wisconsin. She served as a postdoctoral fellow at Massachusetts General Hospital. Prior to joining Genentech, Saroja spent 9 years at the systems modeling biotech, Entelos, Inc, and 2 years as an Associate Director at the rheumatology IVD company, Crescendo Biosciences. Dr Ramanujan has systems pharmacology modeling expertise in numerous therapeutic areas including inflammatory and immune conditions, oncology, and cardiovascular disease.
Steering Committee Members
What is Quantitative Systems Pharmacology?
The white paper below represents the NIH’s attempt to define the opportunities and challenges facing the field of quantitative systems pharmacology (QSP). The paper recommends the adoption of a holistic approach to understanding the interaction of drugs with human biology. The paper further notes that this will require the collaboration and training of scientists from multiple disciplines, from pharmacology to chemistry to computer science. We look forward to hearing from ideas from our SIG members about how these disciplines can be effectively synthesized so that QSP can continue to grow as a field.
Are you interested in receiving updates and participating in SIG discussions? Join the ISoP QSP SIG today, click here. You can also participate in the QSP discussion forum at http://discuss.go-isop.org/c/systems-pharmacology